Results 1 to 10 of about 4,266 (228)

Cardiovascular Risk of Romosozumab vs. Teriparatide: A Cohort Study Using Japan's National Claims Database. [PDF]

Clin Pharmacol Ther
Disproportionality analyses suggested a cardiovascular risk signal for romosozumab, while statistically significant associations were not found in the real‐world database studies. Therefore, a larger comparative study was necessary to examine this signal.
Maruyama H, Iwasa E, Watanabe S, Hasegawa T, Kajiyama K, Tanaka T.   +5 more
europepmc   +2 more sources

Efficacy and safety of romosozumab in patients with chronic kidney disease and osteoporosis: a narrative review. [PDF]

Osteoporos Int
Chronic kidney disease (CKD) is an independent risk factor for osteoporosis. Managing bone loss in CKD patients involves both non-pharmacological and pharmacological strategies.
Abdalbary M, Abdalbary M, Amin AM, Elaraby A, Hassan A.   +4 more
europepmc   +2 more sources

Predictors of clinically meaningful bone mineral density gains with romosozumab: An explainable machine leaning analysis of a real-world cohort. [PDF]

Bone Rep
Objective To evaluate the real-world effectiveness of Romosozumab in postmenopausal women with severe osteoporosis and to identify baseline clinical and biochemical predictors of clinically meaningful bone mineral density (BMD) gains (≥10 %, used for ...
Corredor DC, Pascual LÁC.
europepmc   +2 more sources

Romosozumab versus teriparatide [PDF]

Nature Reviews Rheumatology, 2017
openaire   +1 more source

Assessment of the efficacy and safety of anti-sclerostin antibody therapy for osteoporosis in postmenopausal women: a systematic review and meta-analysis of randomized controlled trials. [PDF]

Front Endocrinol (Lausanne)
Chen L, Wang Q, Gu M.
europepmc   +1 more source

Preliminary analysis of combined romosozumab and denosumab versus teriparatide and denosumab on bone mineral density. [PDF]

Osteoporos Sarcopenia
Chiang MH, Fan TS, Lee CC, Tseng TH, Yen HK, Hung CC, Lu YC, Sie NH, Wang CY, Fu SH.   +9 more
europepmc   +1 more source

From the Editor-in-Chief: Featured Articles in the December 2025 Issue. [PDF]

Neurospine
Han I.
europepmc   +1 more source

Pre-Operative Bone Health in Elective Spine Surgery, From Risk Assessment to Optimization Strategies: A Narrative Review. [PDF]

Global Spine J
Ng MK, Hitchner M, Dalton J, Lee Y, Green WA, Baek G, Mathew J, Eichbaum YK, Hilibrand AS, Vaccaro AR, Schroeder GD, Kepler CK.   +11 more
europepmc   +1 more source

The use of romosozumab versus denosumab in patients with osteoporosis. [PDF]

Rev Assoc Med Bras (1992)
Floriano I, Silvinato A, Bernardo WM.
europepmc   +1 more source

Romosozumab-Induced Epidural Calcification in a Hemodialysis Patient. [PDF]

Cureus
Yoshikawa S.
europepmc   +1 more source